Get the Stockscreener App
3.79
2.43%
0.09
After Hours:
3.79
Ataibeckley Inc stock is traded at $3.79, with a volume of 3.04M.
It is up +2.43% in the last 24 hours and up +2.99% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.70
Open:
$3.58
24h Volume:
3.04M
Relative Volume:
0.68
Market Cap:
$1.38B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-1.644
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
+7.06%
1M Performance:
+2.99%
6M Performance:
-26.26%
1Y Performance:
+156.08%
1-Day Range:
$3.54
$3.80
1-Week Range:
$3.315
$3.80
52-Week Range:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.79 | 1.38B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Why AtaiBeckley (ATAI) Is Up 13.1% After Deutsche Bank Highlights Its Post-Merger Pipeline Potential - simplywall.st
AtaiBeckley Inc. (B72.DE) - Yahoo! Finance Canada
ATAI Stock Price, Quote & Chart | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley - Mugglehead Magazine
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart - Capital.com
Over-the-top psychedelic promos could undermine the field’s drug development efforts - statnews.com
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Is Ataibeckley Inc (ATAI) looking to sell its flagship psychedelic drug candidate BPL-003? - MSN
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide? - simplywall.st
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Yahoo Finance
Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)? - simplywall.st
Deutsche Bank initiates coverage of AtaiBeckley (ATAI) with buy recommendation - MSN
AtaiBeckley Inc. Trade Ideas — TRADEGATE:B72 - TradingView
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts - Yahoo! Finance Canada
AtaiBeckley initiated with a Buy at Deutsche Bank - TipRanks
Deutsche Bank Initiates AtaiBeckley at Buy With $12 Price Target - MarketScreener
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential - Investing.com India
Deutsche Bank Initiates AtaiBeckley(ATAI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential By Investing.com - Investing.com South Africa
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - MSN
H.C. Wainwright Bullish on AtaiBeckley (ATAI) - Insider Monkey
B72 Stock Price and Chart — TRADEGATE:B72 - TradingView
A Look At AtaiBeckley (ATAI) Valuation After Index Inclusions And Positive BPL-003 Phase 2a Results - simplywall.st
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? - Insider Monkey
AtaiBeckley added to S&P Total Market, CRSP benchmark indices By Investing.com - Investing.com Australia
Ataibeckley Insider Sold Shares Worth $355,000, According to a Recent SEC Filing - MarketScreener
5 Best Psychedelic Stocks to Buy in 2026 - insidermonkey.com
AtaiBeckley chief medical officer Craig Kevin James sells $355,000 in stock - Investing.com
AtaiBeckley chief medical officer Craig Kevin James sells $355,000 in stock By Investing.com - Investing.com South Africa
Small cap wrap: Fox Tungsten, AtaiBeckley, Ocean Power Technologies, Abacus Global Management… - Proactive Investors
AtaiBeckley added to major US indices, increasing reach among passive investors - Yahoo Finance
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst - Bitget
AtaiBeckley added to S&P Total Market, CRSP benchmark indices - Investing.com
AtaiBeckley Inc. Added to S&P Total Market Index and CRSP U.S. Benchmark Indices, Enhancing Market Presence and Driving Index Fund Position-Building - quiverquant.com
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg - MSN
AtaiBeckley Inc.(NasdaqGM: ATAI) added to S&P TMI Index - marketscreener.com
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley Advances BPL-003 Program As Beckley Psytech Deal Closes - simplywall.st
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish (NASDAQ:ATAI) - Seeking Alpha
Assessing AtaiBeckley (ATAI) Valuation As Strong Long Term Returns Contrast With Heavy Losses - Yahoo Finance
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating - TipRanks
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):